RESEARCH TRIANGLE PARK,Adherex Technologies has launched the first of three Phase I trials for its proposed cancer drug eniluracil.
Eniluracil was cleared as an investigational new drug in November.
Eniluracil will be used in combination with 5-fluorouracil, a widely used anti-cancer drug, and target solid tumors. If successful, the drug combo would be used in a Phase II trial targeting breast cancer.
Adherex: www.adherex.com
